Clinicopathologic and Genomic Evaluation of Translocation Renal Cell Carcinoma

Daniel E. Nassau1, Alejandro Sanchez1, Renzo Dinatale1, Kyle A. Blum1, Mazyar Ghanaat1, Sounak Gupta2, Maria E. Arcila2, Martin H. Voss3, Robert J. Motzer3, Paul Russo1, Jonathan Coleman1, Ed Reznik4, Victor E. Reuter2, A. Ari Hakimi1

Dept. of Urology1, Dept. of Pathology2, Dept. of Medicine3, Center for Molecular Oncology4, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Introduction

- Translocation renal cell carcinomas (tRCC) are rare, representing ~0.5-5% of all RCC, but are associated with aggressive disease.
- tRCC result from a gene fusion of either Transcription Factor E3 (TFE3), located on Xp11.2, or transcription factor EB (TFEB), on 6p21.2, with various partners, or rarely, TFEB amplification.
- tRCC diagnosis is commonly made by Immunohistochemistry (IHC), Fluorescence in situ hybridization (FISH) and/or next generation sequencing (NGS).

Objective

To characterize the clinicopathologic characteristics and genomics of patients with tRCC.

Methods

- 39 patients with tRCC from 2004 to 2017 were retrospectively reviewed.
  - tRCC was diagnosed using a combination of IHC, FISH and/or MSK-IMPACT, a hybridization capture-based NGS assay for targeted deep sequencing of all exons and selected introns of 468 key cancer genes.

Results

- Median follow-up was 27.4 months (range: 0.4-244.9).
- 16 (41%) patients progressed after surgery with a median progression free survival of 10.5 months (IQR 6.6-27.3).
- 10 (26%) patients died during follow-up with a median overall survival of 28.7 (IQR 26.8-82.0), with 4 (10.2%) patients lost to follow-up.
- 25 (64%) patients had MSK-IMPACT sequencing utilizing either 16 (64%) primary or 9 (36%) metastatic tumor specimens.
  - TERT promoter mutations were found in 12%, all primary samples.
  - Chromatin remodeling gene mutations (SETD2, PBRM1, ATRX, SMARCA4) were found in 12%, all metastatic samples.
  - DNA damage repair gene mutations (ATM, RAD50, BRCA1) were found in 16% of all samples.

Conclusions

- tRCC subtype of RCC presents in younger patients when compared to clear cell RCC (ccRCC). tRCC presents at advanced stages and with a high rate of nodal disease and recurrence.
- We demonstrate, for the first time, additional somatic mutations in the TERT promoter, chromatin remodeling and DNA damage repair gene pathways.
- tRCC have low mutational burdens but also seem to have other somatic mutations involving DNA damage repair pathways.

Future Directions

- Radiology review of cohort to identify predictive features of tRCC preoperatively.
- Review systemic agent efficacy for treatment of advanced disease given IMPACT findings.
- Evaluate differences in gene expression compared to other histologic subtypes of RCC.

Funding

- None